Merck 1Q 1Q Revenues:$11.4 billion (revenues were $5.4 billion in 1Q09) 1Q Earnings: $330.2 million (-77%) Comments: Revenuegrowth in the quarteris largely due to the inclusion of legacy Schering-Plough operations. Singulair sales were $1.2 billion (+10%). Remicade sales were $674 million (+30%). Nasonex sales were $320 million (+4%). Fosamax sales were $230 million (-12%). Clarinex sales were flat at $174 million. Zetia sales were up 5% to $534 million. Vytorin sales were flat at $477 millio...